Edition:
United Kingdom

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

103.50GBp
11 Dec 2017
Change (% chg)

2.90 (+2.88%)
Prev Close
100.60
Open
100.00
Day's High
104.50
Day's Low
99.55
Volume
833,078
Avg. Vol
1,942,990
52-wk High
166.97
52-wk Low
86.50

Chart for

About

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)

Overall

Beta: 0.41
Market Cap(Mil.): £705.16
Shares Outstanding(Mil.): 679.34
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Vectura group announces buyback to return up to £15 million of capital to shareholders​

* ‍vectura group plc (lse: vec) ("vectura", " group"), announces that board has approved a share buyback to return up to £15 million of capital to shareholders​ Source text for Eikon: Further company coverage: (Reporting by Lawrence White)

14 Nov 2017

Falls in Burberry, housebuilders pile pressure on FTSE

LONDON Heavy losses from luxury group Burberry weighed on Britain's top share index on Thursday which hit a two-week low as investors showed anxiety about the retail and housebuilding sectors.

09 Nov 2017

UPDATE 1-Falls in Burberry, housebuilders pile pressure on FTSE

* Mid-cap Hikma's trading update disappoints (ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets)

09 Nov 2017

Britain's FTSE under pressure as Burberry revamps its strategy

LONDON, Nov 9 A drop in luxury group Burberry weighed on the UK's top share index on Thursday, which was stuck below a five-month high as results were the main focus.

09 Nov 2017

UPDATE 1-UK Stocks-Factors to watch on Nov 9

Nov 9 Britain's FTSE 100 index futures are seen opening down 0.1 percent ahead of the cash market open.

09 Nov 2017

BRIEF-Vectura confident on outlook for Novartis inhaler products

* Q3 2017 net sales of $101 million for ultibro ® breezhaler ® and $37 million for seebri ® breezhaler​

24 Oct 2017

BRIEF-Vectura updates on positive Flutiform K-haler regulatory progress

* ‍FLUTIFORM BREATH-ACTIVATED K-HALER MAKES POSITIVE EUROPEAN REGULATORY PROGRESS​

04 Oct 2017

BRIEF-Vectura Group posts HY revenue of 78.8 million pounds

* HY REVENUE 78.8 MILLION POUNDS VERSUS 73.9 MILLION POUNDS A YEAR AGO

06 Sep 2017

BRIEF-Vectura signs VR410 agreement with Pulmatrix

* PROGRESSING DEVELOPMENT OF BRANDED GENERIC TIOTROPIUM BROMIDE PROGRAMME (VR410) FOR US MARKET, ACCELERATED THROUGH LICENCE DEAL WITH PULMATRIX

06 Sep 2017

BRIEF-Vectura announces ANDA filing for US generic version of Advair Diskus

* CONFIRMS STATEMENT MADE BY PARTNER HIKMA IN RESPECT OF ANDA FILING FOR A US GENERIC VERSION OF ADVAIR DISKUS SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE:

17 Aug 2017

Earnings vs. Estimates